Keytruda has been Merck’s can’t-miss drug, rapidly becoming one of the best-selling pharmaceutical products of all time with $14 billion in sales in the first six months of 2024 alone.

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

Acne, psoriasis, chickenpox, and other conditions may cause skin lesions. Seek medical attention if you have a rash or an infection or your lesions resemble those caused by MRSA or cellulitis.

Sep. 16, 2024 — Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...